Managing Clinical Trials Amid Healthcare Policy Reforms: Challenges and Opportunities: Managing Clinical Trials and Healthcare Policy Reforms

Babar Hayat; Naheed Mumtaz; Sadia Choudry; Muhammad Ayub Khan; Amna Iqbal Butt; Zahid Azam Chaudry; Muhammad Hussain

doi:10.54393/pjhs.v5i11.2402

Authors

Babar Hayat Department of Primary and Secondary Healthcare, Government of Pakistan, Lahore, Pakistan
Naheed Mumtaz Faculty of Medical and Health Sciences, University of Poonch, Rawalakot, Pakistan
Sadia Choudry Department of Behavioral Science, Rahbar Medical and Dental College, Lahore, Pakistan
Muhammad Ayub Khan Chughtai Medical Centre, Lahore, Pakistan
Amna Iqbal Butt Department of Community Medicine, Sharif Medical and Dental College, Lahore, Pakistan
Zahid Azam Chaudry Department of Community Medicine, Nazwaz Sharif Medical College, Gujrat, Pakistan
Muhammad Hussain Department of Molecular Pathology, University of Health Sciences, Lahore, Pakistan

DOI:

https://doi.org/10.54393/pjhs.v5i11.2402

Keywords:

Clinical Trials Management, Healthcare Policy Reforms, Patient Recruitment, Challenges

Abstract

Clinical trial management is becoming more influenced by policies in healthcare reform, especially if those reforms are actively affecting regulations, access to healthcare, and compliance. Objectives: To find out the implications of healthcare reforms for the administration, supervision and outcomes of the clinical trials. Methods: This study was carried out according to the PRISMA guidelines. Eight scholarly databases of peer-reviewed research articles were used including PubMed, ScienceDirect, and Google Scholar. For this review, articles published from January 2016 to April 2024 were collected. This paper reviewed articles centred on the impact of healthcare reform policies on clinical trials, especially in chronic diseases and novel therapies in North America, Europe, and Asia. Through screening, 96 articles were taken for initial screening. 16 articles were fully reviewed based on challenges and prospects of clinical trial management in the course of changes in healthcare system reforms. Results: Healthcare policy reforms face obstacles like regulatory challenges, added bureaucracy, and highly volatile patient care accessibility. But there are also some benefits like optimized approval of trials-based procedures, better patient engagement, and increased trial effectiveness. Conclusions: It was concluded that clinical research can be more effective and scalable if proactive adaptive strategies are integrated and trial protocols are aligned with evolving policy changes. Adapting proven trial management practices in healthcare settings has the potential to enhance patient outcomes and promote operational efficiency in clinical research around the world.

References

Hashem H, Abufaraj M, Tbakhi A, Sultan I. Obstacles and Considerations Related to Clinical Trial Research During the COVID-19 Pandemic, (598038). Frontiers in Medicine. 2020 Dec; 7: 1-11. doi: 10.3389/fmed.2020.598038.

Thompson HS, Manning M, Mitchell J, Kim S, Harper FW, Cresswell S et al. Factors Associated with Racial/Ethnic Group–Based Medical Mistrust and Perspectives On COVID-19 Vaccine Trial Participation and Vaccine Uptake in the US. Journal of American Medical Association Network Open. 2021 May; 4(5): e2111629. doi: 10.1001/jamanetworkopen.2021.11629.

Del Paggio JC, Berry JS, Hopman WM, Eisenhauer EA, Prasad V, Gyawali B et al. Evolution of the Randomized Clinical Trial in the Era Of Precision Oncology. Journal of American Medical Association Oncology. 2021 May; 7(5): 728-34. doi: 10.1001/jamaoncol.2021.0379.

Forman R, Atun R, McKee M, Mossialos E. 12 Lessons Learned from the Management of the Coronavirus Pandemic. Health Policy. 2020 Jun; 124(6): 577-80. doi: 10.1016/j.healthpol.2020.05.008.

Manoharan K, Jinson J, Ramesh K, George M. Clinical Trial Trends Over the Last 5 Years among the BRICS (Brazil, Russia, India, China, and South Africa) Nations. Perspectives in Clinical Research. 2024 Jul; 15(3): 128-33. doi: 10.4103/picr.picr_179_23.

Chaudhari N, Ravi R, Gogtay NJ, Thatte UM. Recruitment and Retention of the Participants in Clinical Trials: Challenges and Solutions. Perspectives in Clinical Research. 2020 Apr; 11(2): 64-9. doi: 10.4103/picr.PICR_206_19.

Yip W, Powell-Jackson T, Chen W, Hu M, Fe E, Hu M et al. Capitation Combined with Pay-For-Performance Improves Antibiotic Prescribing Practices in Rural China. Health Affairs. 2014 Mar; 33(3): 502-10. doi: 10.1377/hlthaff.2013.0702.

Rosenberg M, Sheehan S, Zhou E, Pinnow E, Burnell J, Romine M et al. FDA Postmarketing Safety Labeling Changes: What Have We Learned Since 2010 About Impacts On Prescribing Rates, Drug Utilization, And Treatment Outcomes. Pharmaco-epidemiology and Drug Safety. 2020 Sep; 29(9): 1022-9. doi: 10.1002/pds.5073.

Woodcock J and LaVange LM. Master Protocols to Study Multiple Therapies, Multiple Diseases, Or Both. New England Journal of Medicine. 2017 Jul; 377(1): 62-70. doi: 10.1056/NEJMra1510062.

Inan OT, Tenaerts P, Prindiville SA, Reynolds HR, Dizon DS, Cooper-Arnold K et al. Digitizing Clinical Trials. Nature Partner Journals Series Digital Medicine. 2020 Jul; 3(1): 101. doi: 10.1038/s41746-020-0302-y.

Hardy T, Wonders K, Younes R, Aithal GP, Aller R, Allison M et al. The European NAFLD Registry: A Real-World Longitudinal Cohort Study of Nonalcoholic Fatty Liver Disease. Contemporary Clinical Trials. 2020 Nov; 98: 106175. doi: 10.1016/j.cct.2020.106175.

Aldrighetti CM, Niemierko A, Van Allen E, Willers H, Kamran SC. Racial and Ethnic Disparities Among Participants in Precision Oncology Clinical Studies. Journal of American Medical Association Network Open. 2021 Nov; 4(11): e2133205-. doi: 10.1001/jamanetworkopen.2021.33205.

Zhou X, Friedlander S, Kupperman E, Sedarati F, Kuroda S, Hua Z et al. Asia‐Inclusive Global Development of Pevonedistat: Clinical Pharmacology and Translational Research Enabling a Phase 3 Multiregional Clinical Trial. Clinical and Translational Science. 2021 May; 14(3): 1069-81. doi: 10.1111/cts.12972.

Duineveld LA, Vos JA, Wieldraaijer T, Donkervoort SC, Wind J, van Weert HC et al. Recruitment Challenges to the I CARE Study: A Randomized Trial On General Practitioner-Led Colon Cancer Survivorship Care. BioMedical Journal Open. 2021 Aug; 11(8): e048985. doi: 10.1136/bmjopen-2021-048985.

Seino Y, Kim DJ, Yabe D, Tan EC, Chung WJ, Ha KH et al. Cardiovascular and Renal Effectiveness of Empagliflozin in Routine Care in East Asia: Results from the EMPRISE East Asia Study. Endocrinology, Diabetes and Metabolism. 2021 Jan; 4(1): e00183. doi: 10.1002/edm2.183.

Abdelhafiz AS, Abd ElHafeez S, Khalil MA, Shahrouri M, Alosaimi B et al. Factors Influencing Participation in COVID-19 Clinical Trials: A Multi-National Study. Frontiers in Medicine. 2021 Feb; 8: 608959. doi: 10.3389/fmed.2021.608959.

Nakamura K and Shibata T. Regulatory Changes After the Enforcement of the New Clinical Trials Act in Japan. Japanese Journal of Clinical Oncology. 2020 Apr; 50(4): 399-404. doi: 10.1093/jjco/hyaa028.

Fu Z, Jiang M, Wang K, Li J. Minimizing the Impact of the Covid-19 Epidemic on Oncology Clinical Trials: Retrospective Study of Beijing Cancer Hospital. Journal of Medical Internet Research. 2021 Mar; 23(3): e26799. doi: 10.2196/26799.

Laaksonen N, Bengtström M, Axelin A, Blomster J, Scheinin M, Huupponen R. Clinical Trial Site Identification Practices and the Use of Electronic Health Records in Feasibility Evaluations: An Interview Study in the Nordic Countries. Clinical Trials. 2021 Dec; 18(6): 724-31. doi: 10.1177/17407745211038512.

Lythgoe MP, Krell J, Bower M, Murphy R, Marriott J, Blagden SP et al. From the European Medicines Agency to Project Orbis: New Activities and Challenges to Facilitate UK Oncology Drug Approval Following Brexit. The Lancet Oncology. 2023 Apr; 24(4): e150-60. doi: 10.1016/S1470-2045(22)00701-X.

Olympios N, Collet L, Paesmans M, Jungels C, Kotecki N, Awada A et al. Analyses of the Rationale and Implementation of Research Biopsies in Oncology Clinical Trials at a Tertiary Cancer Center. The oncologist. 2021 Dec; 26(12): 1062-70. doi: 10.1002/onco.13906.

Cruz Rivera S, McMullan C, Jones L, Kyte D, Slade A, Calvert M. The Impact of Patient-Reported Outcome Data from Clinical Trials: Perspectives from International Stakeholders. Journal of Patient-Reported Outcomes. 2020 Dec; 4: 1-4. doi: 10.1186/s41687-020-00219-4.

Shafiq N, Kumari S, Kumar V, Suri V, Jayashree M, Duseja A et al. On-site Monitoring of Clinical Trials by an Ethics Committee in India: A Road Less Travelled. Research Ethics. 2021 Jan; 17(1): 45-54. doi: 10.1177/1747016120933923.

Yaakov RA, Güler Ö, Mayhugh T, Serena TE. Enhancing Patient Centricity and Advancing Innovation in Clinical Research with Virtual Randomized Clinical Trials (RCTs). Diagnostics. 2021 Jan; 11(2): 151. doi: 10.3390/diagnostics11020151.

DeVito NJ, Bacon S, Goldacre B. Compliance with Legal Requirement to Report Clinical Trial Results On Clinical trials. Gov: A Cohort Study. The Lancet. 2020 Feb; 395(10221): 361-9. doi: 10.1016/S0140-6736(19)33220-9.

Fogli LK, Aurigemma R, Sommers CL, Singh A, Bourcier K, Ernstoff MS. NCI Cell Therapy Workshop Committee. Challenges and Next Steps in the Advancement of Immunotherapy: Summary of the 2018 and 2020 National Cancer Institute Workshops On Cell-Based Immunotherapy for Solid Tumors. Journal for Immunotherapy of Cancer. 2021; 9(7). doi: 10.1136/jitc-2021-003048.

Wyman Engen N, Huppler Hullsiek K, Belloso WH, Finley E, Hudson F, Denning E et al. A Randomized Evaluation of On-Site Monitoring Nested in a Multinational Randomized Trial. Clinical Trials. 2020 Feb; 17(1): 3-14. doi: 10.1177/1740774519881616.

Robinson R, Sacks L. Decentralized Clinical Trials in the Development of Drugs and Biological Products. Therapeutic Innovation and Regulatory Science. 2024 Feb: 1-3. doi: 10.1007/s43441-023-00612-3.

Cunico C, Vicente G, Leite SN. Initiatives to Promote Access to Medicines After Publication of the Brazilian Policy on the Comprehensive Care of People with Rare Diseases. Orphanet Journal of Rare Diseases. 2023 Aug; 18(1): 259. doi: 10.1186/s13023-023-02881-5.

Michos ED, Reddy TK, Gulati M, Brewer LC, Bond RM, Velarde GP et al. Improving the Enrollment of Women and Racially/Ethnically Diverse Populations in Cardiovascular Clinical Trials: An Practice Statement. American Journal of Preventive Cardiology. 2021 Dec; 8: 100250. doi: 10.1016/j.ajpc.2021.100250.

Epps C, Bax R, Croker A, Green D, Gropman A, Klein AV et al. Global Regulatory and Public Health Initiatives to Advance Pediatric Drug Development for Rare Diseases. Therapeutic Innovation and Regulatory Science. 2022 Nov; 56(6): 964-75. doi: 10.1007/s43441-022-00409-w.

Rajasimha H. The Advent of Patient-Centric Technologies to Combat the High Dropout Rates: Revolutionizing Clinical Trials: Combating Attrition in Clinical Trials: Embracing a Patient-Centric Approach Through Innovative Technologies. Telehealth and Medicine Today. 2024 Apr; 9(2). doi: 10.30953/thmt.v9.474.

Skivington K, Matthews L, Simpson SA, Craig P, Baird J, Blazeby JM, Boyd KA, Craig N, French DP, McIntosh E, Petticrew M. A new framework for developing and evaluating complex interventions: update of Medical Research Council guidance. British Medical Journal. 2021 Sep; 374. doi: 10.1136/bmj.n2061.

De Jong AJ, Van Rijssel TI, Zuidgeest MG, Van Thiel GJ, Askin S, Fons‐Martínez J et al. Opportunities and challenges for decentralized clinical trials: European regulators’ perspective. Clinical Pharmacology and Therapeutics. 2022 Aug; 112(2): 344-52. doi: 10.1002/cpt.2628.

O’Brien EC, Raman SR, Ellis A, Hammill BG, Berdan LG, Rorick T et al. The Use of Electronic Health Records for Recruitment in Clinical Trials: A Mixed Methods Analysis of the Harmony Outcomes Electronic Health Record Ancillary Study. Trials. 2021 Dec; 22: 1-8. doi: 10.1186/s13063-021-05397-0.

Hiramatsu K, Barrett A, Miyata Y. PhRMA Japan Medical Affairs Committee Working Group 1. Current Status, Challenges, and Future Perspectives of Real-World Data and Real-World Evidence in Japan. Drugs Real World Outcomes. 2021 Dec; 8(4): 459-80. doi: 10.1007/s40801-021-00266-3.

Bjerregaard V and Singh R. New Principles in Global Development Using ICH E 17 Guideline. In Simultaneous Global New Drug Development. 2021 Dec; 11-30. doi: 10.1201/9781003109785-2.

Mateo J, Steuten L, Aftimos P, André F, Davies M, Garralda E et al. Delivering Precision Oncology to Patients with Cancer. Nature Medicine. 2022 Apr; 28(4): 658-65. doi: 10.1038/s41591-022-01717-2.